Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Olema Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PALAZESTRANT IN COMBINATION WITH RIBOCICLIB DEMONSTRATED ENCOURAGING ACTIVITY ACROSS ALL DOSE COHORTS AND SUBGROUPS MEDIAN PFS WAS 15.5 MONTHS IN THE 120 MG PALAZESTRANT COHORT ACROSS ALL PATIENTS IN THE 120 MG PALAZESTRANT COHORT AMONG PATIENTS WITH PRIOR CDK4/6I TREATMENT, MEDIAN PFS WAS 9.2 MONTHS IN PATIENTS WITH ESR1 WILD-TYPE TUMORS AND 13.8 MONTHS IN PATIENTS WITH ESR1 MUTANT TUMORS COMBINATION CONTINUES TO DEMONSTRATE FAVORABLE TOLERABILITY AND A SAFETY PROFILE CONSISTENT WITH THE KNOWN PROFILES OF EACH DRUG DATA SUPPORT THE ONGOING PHASE 3 OPERA-02 TRIAL OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN FRONTLINE ADVANCED OR METASTATIC BREAST CANCER SAN FRANCISCO, OCT. 18, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED UPDATED DATA FROM THE PHASE 1B/2 STUDY OF PALAZESTRANT IN COMBINATION WITH RIBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE (ER+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER. THESE FINDINGS WILL BE PRESENTED IN A POSTER SESSION ON OCTOBER 20 AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) CONGRESS 2025 IN BERLIN, GERMANY.

OLEMA ONCOLOGY ANNOUNCES NEW DATA FROM THE PHASE 1B/2 TRIAL OF PALAZESTRANT PLUS RIBOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER AT ESMO 2025

SAN FRANCISCO, OCT. 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO THREE NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 77,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF OCTOBER 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

SAN FRANCISCO, SEPT. 03, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 124,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF SEPTEMBER 2, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

STUDY TO EXPLORE THE PALAZESTRANT-ATIRMOCICLIB COMBINATION IN APPROXIMATELY 35 PATIENTS WITH INITIATION ANTICIPATED IN H2 2025 RESULTS TO INFORM POTENTIAL PIVOTAL PHASE 3 TRIAL OF NOVEL COMBINATION IN FRONTLINE METASTATIC BREAST CANCER SETTING SAN FRANCISCO, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND,TODAY ANNOUNCED A NEW CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH PFIZER INC. (NYSE: PFE) IN METASTATIC BREAST CANCER.

OLEMA ONCOLOGY ANNOUNCES NEW CLINICAL TRIAL AGREEMENT WITH PFIZER TO COMBINE PALAZESTRANT WITH ATIRMOCICLIB IN ER+/HER2- METASTATIC BREAST CANCER

SAN FRANCISCO, AUG. 20, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC.(OLEMA, OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

OLEMA ONCOLOGY TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

SAN FRANCISCO, AUG. 11, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY REPORTED FINANCIAL AND OPERATING RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025.

OLEMA ONCOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL AND OPERATING RESULTS

SAN FRANCISCO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 130,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF AUGUST 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, JULY 02, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO FOUR NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 154,500 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF JULY 1, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, JUNE 03, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED THAT THE COMPANY GRANTED STOCK OPTIONS TO 11 NEW EMPLOYEES TO PURCHASE AN AGGREGATE OF 322,000 SHARES OF THE COMPANY'S COMMON STOCK, EFFECTIVE AS OF JUNE 2, 2025. THESE AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF OLEMA'S BOARD OF DIRECTORS AND GRANTED UNDER THE COMPANY'S 2022 INDUCEMENT PLAN AS AN INDUCEMENT MATERIAL TO THE NEW EMPLOYEES ENTERING INTO EMPLOYMENT WITH OLEMA, IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4).

SAN FRANCISCO, MAY 28, 2025 (GLOBE NEWSWIRE) -- OLEMA PHARMACEUTICALS, INC. (OLEMA OR OLEMA ONCOLOGY, NASDAQ: OLMA), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DISCOVERY, DEVELOPMENT, AND COMMERCIALIZATION OF TARGETED THERAPIES FOR BREAST CANCER AND BEYOND, TODAY ANNOUNCED IT HAS ALIGNED WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO SELECT 90 MG OF PALAZESTRANT AS THE DOSE FOR PART 2 OF THE ONGOING REGISTRATIONAL PHASE 3 OPERA-01 TRIAL IN SECOND- AND THIRD-LINE ESTROGEN RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (ER+/HER2-) METASTATIC BREAST CANCER. THIS UPDATE WILL BE PRESENTED AS PART OF THE OPERA-01 TRIAL-IN-PROGRESS POSTER AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TAKING PLACE MAY 30-JUNE 3 IN CHICAGO, ILLINOIS. THE FDA ALSO SELECTED 90 MG OF PALAZESTRANT IN COMBINATION WITH THE APPROVED DOSE OF CDK4/6 INHIBITOR RIBOCICLIB FOR THE PIVOTAL PHASE 3 OPERA-02 TRIAL IN FRONTLINE ER+/HER2- METASTATIC BREAST CANCER.

Olema Pharmaceuticals, Inc.

OLMA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Olema Pharmaceuticals, Inc.

OLMA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

OLMA